http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2692340-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6d77e120d1588e76c73afc1a3197a126 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6031 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385 |
| filingDate | 2008-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4ec4dcd70a61d244e10089cf722c754 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3b915fcadc94a4fceba46a6afd9015a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d390aed058360bb79dc4ce07c69845a1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5753e8bfd8efc03af04c17412dee50de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37a7df3018f92f6e99687baf5b3d45b4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f378c27db62ffff8203ce90c88373a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c754871b1e1684c905f13a0d206ff6e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0474f7af5f34b32bc3161065aa3305d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4122c56f101fa690f193ea63c787493f |
| publicationDate | 2009-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2692340-A1 |
| titleOfInvention | Production of an homogeneous vaccine preparation for cancer treatment |
| abstract | The present invention concerns the biotechnology sector and more specifically human healthcare. In particular, the present invention describes a vaccine composition for therapeutic use thereof on cancer patients. The vaccine composition described in the present invention has as active principle a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and recombining protein P64k. In addition, specific conditions are described for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. In another embodiment the present invention concerns a method for purification of the chemical conjugate which not only provides greater purity for the therapeutic composition, but surprisingly increases the immunogenic activity, causing significant increases in the anti-EGF antibody titres in humans. In addition the present invention provides the methodology for producing a vaccine preparation with more than one type of dose presentation (total milligrams of EGF-P64k conjugates/vial). This versatility in the presentation of the vaccine preparation enables the immunization dose per patient to be increased, but without involving an increase in immunization frequency and/or the number of immunization sites. Finally, the present invention involves a healthcare method for producing the vaccine for cancer therapy, administered by parenteral means. |
| priorityDate | 2007-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.